Alfasigma To Acquire Intercept Pharmaceuticals For $19.00 Per Share In Cash, Expanding The Global Footprint Of Alfasigma Via A Leader In Rare And Serious Liver Diseases
Acquiring Company
Alfasigma
Acquired Company
Intercept Pharmaceuticals
Bologna
MorristownManufacturingBiotechnologyHealth CareDescription
Alfasigma S.p.A (“Alfasigma”), one of Italy's leading pharmaceutical companies, and Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT, “Intercept”), a leading biopharmaceutical company in rare and serious liver diseases, today announced that they have entered into a definitive merger agreement under which Alfasigma has agreed to acquire Intercept for $19.00 per share in cash. The anticipated transaction will materially expand Alfasigma’s gastrointestinal and hepatology portfolio and its presence in the U.S. market.
Who to call at Alfasigma, and when
When Alfasigma changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Alfasigma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Alfasigma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alfasigma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alfasigma makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Intercept Pharmaceuticals?
Intercept Pharmaceuticals was acquired by Alfasigma, based in Bologna. The deal was reported on September 26, 2023. Alfasigma is one of Italy's leading pharmaceutical companies with a strong international position. Alfasigma is privately held and operates in Manufacturing.
When did Alfasigma acquire Intercept Pharmaceuticals?
Alfasigma's acquisition of Intercept Pharmaceuticals was reported on September 26, 2023. Alfasigma S.p.A (“Alfasigma”), one of Italy's leading pharmaceutical companies, and Intercept Pharmaceuticals, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Intercept Pharmaceuticals do?
We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). It is privately held, and is based in Morristown.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.